Puberty blocker trial will help reduce harm, says Cass report author
Summary
A clinical trial will study puberty blockers for children questioning their gender to understand their risks and benefits. Dr. Hilary Cass, who led a review on gender medicine, says the trial is important to prevent harm and improve care, with safeguards to protect participants.Key Facts
- The trial will study drugs that delay puberty in gender-questioning children as young as 11.
- Dr. Hilary Cass supports the trial, saying not doing it could lead to more harm.
- The trial will measure physical, social, and emotional effects, including bone health and fertility.
- Medication like testosterone, which causes permanent changes, is currently not allowed for under-16s in the UK.
- The UK government banned private and NHS prescriptions of puberty blockers in 2024 but supports this research.
- Enrollment for the trial will start in August, after setting minimum ages and safety measures.
- Some campaigners oppose the trial, arguing children cannot fully consent and that it might cause irreversible harm.
- Health Secretary James Murray emphasized the need for clinical evidence and safeguards for young participants.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.